Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Chief Operating Officer | August 21, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyell Immunopharma, Inc.
Report date August 21, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,816 |
Reported balance
After 2026-08-21 transaction · row 1
1 source rowRow 1 · 2026-08-21 · Sale · Disposed 989 · Balance 16,816 F1: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2026 Filed Aug 25, 2026 20:05 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 989 | $15.54 | $15,369.06 |
DisclosureSEC source: 0001866154-26-000006 · form4-08252026_080813.xml · nonDerivative · entry 1 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,816 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 20:18 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 89 | $14.34 | $1,276.26 |
DisclosureSEC source: 0001866154-26-000004 · form4-08112026_080811.xml · nonDerivative · entry 1 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,805 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.27 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 11, 2026 Filed Jun 15, 2026 22:34 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 89 | $18.92 | $1,683.88 |
DisclosureSEC source: 0001866154-26-000003 · form4-06152026_100659.xml · nonDerivative · entry 1 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,894 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.30 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Includes 188 shares acquired on May 18, 2026 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 01:46 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 1,236 | $23.39 | $28,910.04 |
DisclosureSEC source: 0001866154-26-000002 · form4-02132026_010228.xml · nonDerivative · entry 1 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,795 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units. F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 02:05 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $23.71 | $0.00 |
DisclosureSEC source: 0001866154-26-000001 · form4-02122026_020218.xml · derivative · entry 3 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-02-09 F4 · derivative.exercise_date: Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 02:05 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 109 | $23.12 | $2,520.08 |
DisclosureSEC source: 0001866154-26-000001 · form4-02122026_020218.xml · nonDerivative · entry 2 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,031 F3 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:05 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001866154-26-000001 · form4-02122026_020218.xml · nonDerivative · entry 1 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,140 F1 · shares: Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date. F2 · balance_after: Includes 390 shares acquired on November 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 01:31 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 95 | $16.12 | $1,531.40 |
DisclosureSEC source: 0001866154-25-000006 · form4-11132025_011153.xml · nonDerivative · entry 1 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 21:42 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 75,000 | $0.00 Strike: $17.23 | $0.00 |
DisclosureSEC source: 0001866154-25-000005 · form4-10292025_091048.xml · derivative · entry 2 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-10-26 F1 · derivative.exercise_date: 12.5% of the option shares will vest on April 27, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 20:06 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 1,004 | $10.54 | $10,586.18 |
DisclosureSEC source: 0001415889-25-022746 · form4-08222025_080857.xml · nonDerivative · entry 2 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,845 F2 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F3 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 20:06 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022746 · form4-08222025_080857.xml · nonDerivative · entry 1 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,849 F1 · shares: Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 4,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 01:09 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 94 | $10.34 | $971.77 |
DisclosureSEC source: 0001415889-25-021693 · form4-08142025_010830.xml · nonDerivative · entry 2 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,849 F5 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F6 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F7 · balance_after: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:09 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 91 | $10.53 | $957.87 |
DisclosureSEC source: 0001415889-25-021693 · form4-08142025_010830.xml · nonDerivative · entry 1 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,943 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan. F4 · balance_after: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. Read SEC document |
| February 10, 2025 Filed Feb 27, 2025 00:31 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 56,250 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001415889-25-005760 · form4-02272025_120219.xml · derivative · entry 3 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2035-02-09 F4 · derivative.exercise_date: The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria. Read SEC document |
| February 10, 2025 Filed Feb 27, 2025 00:31 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 450,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001415889-25-005760 · form4-02272025_120219.xml · derivative · entry 2 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2035-02-09 F3 · derivative.exercise_date: 12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date. Read SEC document |
| February 10, 2025 Filed Feb 27, 2025 00:31 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantCommon Stock | 112,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005760 · form4-02272025_120219.xml · nonDerivative · entry 1 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,899 F1 · kind: 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date. F2 · balance_after: Includes 7,707 shares acquired on May 17, 2024 and 3,764 shares acquired on November 18, 2024 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:24 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-24-003274 · doc4.xml · derivative · entry 2 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2034-02-08 F3 · derivative.exercise_date: 12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:24 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003274 · doc4.xml · nonDerivative · entry 1 Hill Stephen J. · CIK 0001866154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,928 F1 · date: The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 2,941 shares acquired on May 18, 2022, 5,434 shares acquired on May 18, 2023 and 553 shares acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | Disposition to issuerStock Option (right to buy) · Derivative | 700,000 | Not disclosed Strike: $5.98 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 13 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 700,000 shares Expires 2032-03-15 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F14 · derivative.exercise_date: 12.5% of the option shares vested on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantStock Option (right to buy) · Derivative | 700,000 | Not disclosed Strike: $1.87 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 12 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2032-03-15 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F13 · derivative.exercise_date: 306,250 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following thirty-nine months based on the original vesting commencement date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | Disposition to issuerStock Option (right to buy) · Derivative | 85,000 | Not disclosed Strike: $12.67 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 11 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires 2031-04-13 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F12 · derivative.exercise_date: 1/48th of the total shares vest in equal monthly installments over the forty-eight months following April 14, 2021. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantStock Option (right to buy) · Derivative | 85,000 | Not disclosed Strike: $1.87 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 10 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2031-04-13 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F11 · derivative.exercise_date: 54,896 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following twenty-nine months based on the original vesting commencement date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $6.24 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 9 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2031-02-11 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F10 · derivative.exercise_date: 1/48th of the total shares vest in equal monthly installments over the forty-eight months following March 1, 2021. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $1.87 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 8 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-02-11 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F9 · derivative.exercise_date: 66,667 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following twenty-eight months based on the original vesting commencement date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | Disposition to issuerStock Option (right to buy) · Derivative | 450,000 | Not disclosed Strike: $5.96 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 7 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,000 shares Expires 2030-11-16 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F8 · derivative.exercise_date: 1/48th of the total shares vest in equal monthly installments over the forty-eight months following December 1, 2020. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantStock Option (right to buy) · Derivative | 450,000 | Not disclosed Strike: $1.87 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 6 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2030-11-16 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F7 · derivative.exercise_date: 328,125 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following twenty-five months based on the original vesting commencement date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | Disposition to issuerStock Option (right to buy) · Derivative | 165,000 | Not disclosed Strike: $3.65 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 5 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 165,000 shares Expires 2030-01-15 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F6 · derivative.exercise_date: 1/48th of the total shares vest in equal monthly installments over the forty-eight months following February 1, 2020. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantStock Option (right to buy) · Derivative | 165,000 | Not disclosed Strike: $1.87 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 4 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2030-01-15 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F5 · derivative.exercise_date: 154,688 shares were vested as of November 16, 2023 and the remaining unvested shares will vest in equal monthly installments over the following fifteen months based on the original vesting commencement date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | Disposition to issuerStock Option (right to buy) · Derivative | 500,000 | Not disclosed Strike: $3.65 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 3 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2029-11-30 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F2 · derivative.exercise_date: Fully-vested. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 01:52 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantStock Option (right to buy) · Derivative | 500,000 | Not disclosed Strike: $1.87 | Not disclosed |
DisclosureSEC source: 0001209191-23-056178 · doc4.xml · derivative · entry 2 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-11-30 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options. F2 · derivative.exercise_date: Fully-vested. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 23:21 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 900,000 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001209191-23-013850 · doc4.xml · derivative · entry 2 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2033-02-23 F2 · derivative.exercise_date: 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 700,000 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001209191-22-020001 · doc4.xml · derivative · entry 1 Hill Stephen J. · CIK 0001866154 · Chief Technical Ops. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2032-03-15 F1 · derivative.exercise_date: 12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.